Objective SLE is a multisystem autoimmune disease characterised by chronic inflammation and progressive organ damage, ...

As researchers work to make death optional, investors see a chance for huge returns. But has the human body already reached ...

Aqtual’s proprietary platform evaluates protein regulation, epigenetics, and transcriptomics solely using cell-free DNA fragments found in the blood.

On June 18, 2025, the U.S. Food and Drug Administration (FDA) announced that it will review new clinical trials that involve sending ...

Figure 4. Donor derived cell-free DNA percentage is detectable at fulminant graft rejection. Cell free DNA was isolated from blood samples collected from recipient animals. The isolated DNA was then ...

PEDAL is the first prospective multi-center trial evaluating longitudinal trends of donor-derived cell-free DNA (dd-cfDNA) to determine the prognostic ability of Prospera in assessing outcomes ...

Rheumatoid arthritis is a chronic, systemic autoimmune disease characterized by systemic inflammation and progressive joint destruction. Current treatments include conventional disease-modifying ...

The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA's deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the ...

The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA’s deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the ...

The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA’s deep expertise in large-scale PCR. Unlike conventional plasmid-based DNA production methods, the ...

About the LineaDNA™ and LineaIVT™ Platforms The LineaDNA platform is a proprietary, cell-free DNA production system leveraging Applied DNA’s deep expertise in large-scale PCR.